The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Interleukin-33 in atopic dermatitis
Abstract
Atopic dermatitis (AD) is characterized by pruritus, barrier disruption, and inflammationincluding type 2 cytokine production. Interleukin-33 (IL-33) is an inflammatory cytokine that is over-expressed in the keratinocytes of patients with AD. IL-33 transgenic mice, which express IL-33 specifically in keratinocytes, spontaneously develop AD-like eczema, suggesting that IL-33 is sufficient for the development of AD. IL-33 stimulates various cells, including group 2 innate lymphoid cells (ILC2s), to produce type 2 cytokines, such as IL-5 and IL-13, and IL-33-stimulated basophils activate ILC2s via IL-4. ILC2s are enriched in human AD skin lesions, and ILC2 isolated from AD lesions, are activated by IL-33, not by thymic stromal lymphopoietin (TSLP). IL-33 induces IL-31, thereby promoting pruritus and scratching behavior. Conversely, scratching the skin promotes IL-33 release from keratinocytes. IL-33 reduces the expression of filaggrin and claudin-1; it also reduces the skin barrier function. However, barrier destruction causes percutaneous exposure to allergens or IL-33 release. Thus, IL-33 is a common point of entry into the itch-scratch cycle of AD. These new findings can facilitate the development of novel therapeutic drugs targeting IL-33.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis
Simpson, E. L., Bieber, T., Guttman-Yassky, E., Beck, L. A., Blauvelt, A., Cork, M. J., Silverberg, J. I., Deleuran, M., Kataoka, Y., Lacour, J.-P., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1610020 · Cited by 2,110
Weidinger, S., Beck, L. A., Bieber, T., Kabashima, K., & Irvine, A. D. (2018) · Nature Reviews Disease Primers · doi:10.1038/s41572-018-0001-z · Cited by 1,549
Moussion, C., Ortega, N., & Girard, J.-P. (2008) · PLoS ONE · doi:10.1371/journal.pone.0003331 · Cited by 1,179
A critical role of IL-33 in experimental allergic rhinitis
Haenuki, Y., Matsushita, K., Futatsugi-Yumikura, S., Ishii, K. J., Kawagoe, T., Imoto, Y., Fujieda, S., Yasuda, M., Hisa, Y., Akira, S., et al. (2012) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2012.02.013 · Cited by 233
Interleukin‐31 and interleukin‐31 receptor: New therapeutic targets for atopic dermatitis
Nakashima, C., Otsuka, A., & Kabashima, K. (2018) · Experimental Dermatology · doi:10.1111/exd.13533 · Cited by 154
Cited by
Cytokinocytes: the diverse contribution of keratinocytes to immune responses in skin
Jiang, Y., Tsoi, L. C., Billi, A. C., Ward, N. L., Harms, P. W., Zeng, C., Maverakis, E., Kahlenberg, J. M., & Gudjonsson, J. E. (2020) · JCI Insight · doi:10.1172/jci.insight.142067 · Cited by 348
Keratinocytes: innate immune cells in atopic dermatitis
Chieosilapatham, P., Kiatsurayanon, C., Umehara, Y., Trujillo-Paez, J. V., Peng, G., Yue, H., Nguyen, L. T. H., & Niyonsaba, F. (2021) · Clinical and Experimental Immunology · doi:10.1111/cei.13575 · Cited by 217
Peripheral itch sensitization in atopic dermatitis
Tominaga, M., & Takamori, K. (2022) · Allergology International · doi:10.1016/j.alit.2022.04.003 · Cited by 160
Fania, L., Moretta, G., Antonelli, F., Scala, E., Abeni, D., Albanesi, C., & Madonna, S. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23052684 · Cited by 128
Alarmin cytokines as central regulators of cutaneous immunity
Hasegawa, T., Oka, T., & Demehri, S. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.876515 · Cited by 70
Metadata
- Authors
- Imai, Y.
- Venue
- Journal of Dermatological Science
- Publisher
- Elsevier BV
- Published
- 2019-10
- Volume
- 96
- Issue
- 1
- Pages
- 2-7
- ISSN
- 0923-1811 (ISSN-L)
- OpenAlex
- W2969959484
- Cited by
- 209
- References
- 5
- FWCI
- 18.83
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Interleukin-33 in atopic dermatitis. https://app.cochat.ai/papers/10.1016/j.jdermsci.2019.08.006
- The paper
- Imai, Y. (2019). Interleukin-33 in atopic dermatitis. Journal of Dermatological Science. https://doi.org/10.1016/j.jdermsci.2019.08.006
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.